This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Taisho Pharmaceutical Co., Ltd.. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Eiji Munetomo: Innovator in Pharmaceutical Compounds
Introduction: Eiji Munetomo is a prominent inventor based in Tokyo, Japan. He is known for his contributions to the field of pharmaceuticals, particularly in the development of innovative compounds. His work has significant implications for medical science and therapeutic applications.
Latest Patents: Eiji Munetomo holds a patent for a phenyl tetrahydroisoquinoline compound substituted with heteroaryl. This invention provides a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, which has an excellent NHE3 inhibitory effect. This advancement is crucial for developing new treatments in the pharmaceutical industry.
Career Highlights: Munetomo is associated with Taisho Pharmaceutical Co., Ltd., where he has made significant strides in research and development. His expertise in pharmaceutical compounds has positioned him as a valuable asset in the company.
Collaborations: Throughout his career, Eiji Munetomo has collaborated with notable colleagues, including Shoichi Kuroda and Kenichi Kawabe. These partnerships have fostered innovation and contributed to the success of various projects.
Conclusion: Eiji Munetomo's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His contributions continue to influence the development of new therapeutic compounds, showcasing the importance of research and collaboration in advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile